The market for neurodegenerative therapeutics.

Currently there are no remedies that prevent or halt the progression of these diseases.

Alzheimer's disease, Parkinson's disease and an array of related disorders that are characterized by progressive neuronal loss are a huge and increasing health care problem affecting millions worldwide. The only available therapeutics have limited efficacy and only treat the symptoms.

Neurodegenerative disorders are a dire public health problem

Alzheimer's Disease (AD) is arguably the most dire health problem facing the Western World. It is estimated that 50% of people over 85 will have or acquire Alzheimer's; this translates into a huge market as advances in medicinal technology have extended life expectancy of the US population.

A multi-billion dollar drug market

The current size of Alzheimer's-drug market is an estimated $3 billion, with up to 12 million people suffering from the condition in the U.S., Europe and Japan. The market could possibly surpass $20 billion with the approval of a disease-modifying drug. The key growth driver for Alzheimer's drugs is undoubtedly an aging population.
Development of disease modifying therapeutics requires an understanding of the most basic mechanisms underlying these disorders. The drugs that are currently prescribed to treat AD do not affect the course of the disease, they only treat symptoms, leaving the underlying cause and inevitable attack of this devastating disorder. Signum's approach has the promise to transform Alzheimer's disease therapeutics to make a huge impact in a critical market.